Bristol-Myers Squibb Company (NYSE:BMY) registered a 1.96% increase, still its new closing price is 3.76% up from the company’s 1 year high of 76.09.It posted -3.03% losses in previous 5 sessions and is now the subject of 11 analysts who together assign a hold rating on stock. 1 of Wall Street analysts have an underperform rating; the 1 sells versus 7 buy or better ratings. The 23 stock analysts following this company have an average price target at $56.69, with individual PT in the $42.00-$70.00 range. The shares moved at $47.74, implying that brokerage firms see shares losing about -19.99% in twelve months time.

Bristol-Myers Squibb Company (BMY) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a -17.77% fall year to date. A Director at Bristol-Myers Squibb Company (BMY) offloaded shares in a transaction closed on Thursday September 08, 2016. ANDREOTTI LAMBERTO sold 21,600 shares in the company at $56.87 each and collected $1,228,000 in proceeds. ANDREOTTI LAMBERTO now owns 423,699 shares in the company after this transaction. A Director in the company, ANDREOTTI LAMBERTO, disclosed a transaction on Thursday August 25, 2016 that ended up generating $1,372,001 from the sale of 23,200 shares at $59.17 per share.

Bristol-Myers Squibb Company (NYSE:BMY) Upcoming Results on Tap

Bristol-Myers Squibb Company will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $0.73 in that period. Sales during the quarter are predicted to arrive at $4.75 billion.

Earnings surprise history: Last quarter, the company posted approximately $5.24 billion in revenue and EPS of $0.63. The mean forecast was for $5.12 billion and $0.67 a share, respectively. One quarter earlier, revenue for the stock was at $4.92 billion, with earnings at $0.77/share.

Bristol-Myers Squibb Company (BMY) Brokerage Update

Bristol-Myers Squibb Company (BMY) is in Jefferies’s research list so their analyst rating change is noteworthy. These shares were upgraded to Buy from Hold by Jefferies, according to news reported on Monday December 19, 2016.Another important research note was issued by Berenberg on Thursday August 11, 2016.The firm downgraded BMY to Hold from Buy. Over the last six months and over the last three months, the shares of Bristol-Myers Squibb Company (BMY), have changed -35.19% and -2.51%, respectively.